Here are the Form 4 insider transactions from Regencell Bioscience Holdings Limited (RGC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RGC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGC filings page.
Regencell Bioscience Holdings Ltd (RGC) director William Wing Yan Lo exercised options for 36,001 ordinary shares on November 17, 2026, at an exercise price of $0.84 per share. The price reflects the issuer’s share splits since the options were granted. After the exercise, he directly held 485,629 ordinary shares.
Regencell Bioscience Holdings Ltd director Dr. William Wing Yan Lo reported a disposition of stock options back to the company. On May 27, 2026, the issuer repurchased options covering 70,600 ordinary shares at $15.00 per option, which had an exercise price of $0.84 per share. Following this transaction, Dr. Lo held 521,630 stock options directly in the same security class. The filing characterizes the event as a disposition to the issuer rather than an open-market trade.
Regencell Bioscience Holdings Ltd director HUI EVANA YEE WAH reported a disposition of stock options back to the company. On May 27, 2026, the issuer repurchased options to purchase 19,000 ordinary shares at $15.00 per option under an Option Repurchase Agreement.
The repurchased options had an exercise price of $0.25 per share. Following this issuer disposition, the reporting person is shown with 573,230 shares related to this security, indicating she retains a substantial position after the transaction.